Heme Interacts with C1q and Inhibits the Classical Complement Pathway*

Received for publication, November 23, 2010, and in revised form, March 1, 2011 Published, JBC Papers in Press, March 22, 2011, DOI 10.1074/jbc.M110.206136

Lubka T. Roumenina1,2, Maria Radanova3, Boris P. Atanassov4,5, Krastio T. Popov1,2, Srinivas V. Kaveri5, Sébastien Lacroix-Desmazes1,5,6, Véronique Fréméaux-Bacchi5,6, and Jordan D. Dimitrov2,3,4
From the 1Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris 6, UMR S 872, Paris F-75006, France, the 2Inserm, U872, Paris F-75006, France, the 3Department of Biochemistry, Molecular Medicine and Nutrigenomics Medical University Varna, 9002 Varna, Bulgaria, the 4Biophysical Chemistry Group, Institute of Organic Chemistry, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria, the 5German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany, and the 6Assistance Publique-Hopitaux de Paris, Hopital European Georges-Pompidou, Service d’Immunologie Biologique, 75098 Paris, France

C1q is the recognition subunit of the first component of the classical complement pathway. It participates in clearance of immune complexes and apoptotic cells as well as in defense against pathogens. Inappropriate activation of the complement contributes to cellular and tissue damage in different pathologies, urging the need for the development of therapeutic agents that are able to inhibit the complement system. In this study, we report heme as an inhibitor of C1q. Exposure of C1q to heme significantly reduced the activation of the classical complement pathway, mediated by C-reactive protein (CRP) and IgG. Interaction analyses revealed that heme reduces the binding of C1q to CRP and IgG. Furthermore, we demonstrated that the inhibition of C1q interactions results from a direct binding of heme to C1q. Formation of complex of heme with C1q caused changes in the mechanism of recognition of IgG and CRP. Taken together, our data suggest that heme is a natural negative regulator of the classical complement pathway at the level of C1q. Heme may play a role at sites of excessive tissue damage and hemolysis where large amounts of free heme are released.

The complement system is among the first lines of defense against pathogens and is a sensor for altered self (1, 2). A set of recognition molecules detect foreign and altered self structures and trigger one of the three complement pathways, referred to as classical, lectin, and alternative (3). The three pathways merge at the level of the central component C3 to execute a common terminal pathway leading to inflammation, pathogen opsonization, and lysis. When the complement cascade is triggered on altered self, it is tightly regulated to proceed to clearance of apoptotic cells and debris without inducing inflammation (3, 4). The recognition molecule of the classical complement pathway C1q has a complex topology, consisting of six globular (gC1q)5 heterotrimer domains and a collagen-like region (5). C1q detects pathogen associated patterns (6). It also recognizes immunoglobulins (IgG and IgM) and pentraxins (such as C-reactive protein, CRP) (7) bound to their targets. CRP exists as a pentamer (8, 9) in solution and is considered to dissociate to monomers once bound to a membrane (10, 11). C1q was reported to recognize both forms of CRP. C1q also binds and participates in the clearance of host apoptotic cells and debris. Complement activation and regulation are balanced in physiological conditions, but complement dysregulation is responsible for severe tissue damage in a variety of pathological conditions. Therefore, specific inhibitors of complement are needed for clinical practice (12).

Pathological activation of complement has been associated with ischemic tissue after reperfusion, autoimmune hemolytic anemia, lupus nephritis, and etc. (13–15). In these conditions the alternative and/or lectin pathways are mostly involved. In these conditions, tissue or cellular damages are often accompanied by the release of large amounts of intracellular macromolecules and low molecular weight compounds including heme (16, 17). Heme (iron protoporphyrin IX) is a macrocyclic compound utilized as prosthetic group by many proteins for gas transport and oxidative metabolism. Tissue damage and hemolysis were shown to result in release of heme from hemo-proteins such as hemoglobin, myoglobin, and cytochromes (16–19). Free heme is redox-active and cytotoxic (16, 20). Therefore, it must be scavenged and removed quickly from the circulation. This is achieved by heme-binding plasma proteins such as hemopexin, α-microglobulin and albumin (16). However, as a result of excessive tissue damage and hemolysis, heme-binding proteins are saturated, and high local and/or systemic concentrations of heme (>20 μM) may be achieved (18, 21). In such situations, heme accumulates in the endothelial cells membranes and plasma lipoproteins, imposing oxidative

*This work was supported by the Institut National de la Santé et de la Recherche Médicale (France), by Centre National de la Recherche Scientifique (France), and by Université Pierre et Marie Curie (Paris 6).
**The on-line version of this article (available at http://www.jbc.org) contains supplemental “Experimental Procedures” and Fig. 1.
1Supported by the French-Bulgarian Project EGIDE Rila 19296UK.
2Recipient of a European Molecular Biology Organization long-term fellowship. To whom correspondence may be addressed: Equipe 13 INSERM UMR S 872, Centre de Recherche des Cordeliers, 15 rue de l’Ecole de Médecine, 75006 Paris, France. Tel.: 33-0-1-44-27-90-96; Fax: 33-0-1-40-51-04-20; E-mail: lubka.roumenina@crc.jussieu.fr.
3Supported by Bulgarian National Fund for Science Research Grant X-1310.
4Recipient of a fellowship from the Fondation pour le Recherche Médicale (Paris, France). To whom correspondence may be addressed: Equipe 16 INSERM UMR S 872, Centre de Recherche des Cordeliers, 15 rue de l’Ecole de Médecine, 75006 Paris, France. Tel.: 33-0-1-55-42-82-71; Fax: 33-0-1-55-42-82-62; E-mail: jordan.dimitrov@crc.jussieu.fr.

The abbreviations used are: gC1q, globular C1q; MAC, membrane attack complex; PP, protoporphyrin IX; PnC, pneumococcal C-polysaccharide.

© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
stress and inflammation (21, 22). Heme also interacts with various plasma proteins and modulates their functions (23–26). We have demonstrated previously that in vitro exposure of C1q to heme results in concentration-dependent inhibition of C1q binding to its main targets, IgG and CRP (27). The underlying mechanisms of this inhibition, however, remain poorly understood. In the present study, we investigated the functional aspect and the molecular mechanisms of inhibition of C1q by heme. We identify heme as an endogenous negative regulator of the classical complement pathway activation that acts at the level of C1q and may play a role at sites of excessive tissue damage and hemolysis.

EXPERIMENTAL PROCEDURES

Materials—The oxidized form of heme (ferriprotoporphyrin IX chloride) was obtained from Fluka (Taufkirchen, Germany), hematoporphyrin IX was obtained from Sigma-Aldrich. The Zn(II) protoporphyrin IX (Zn(II)PP), Mg(II)PP, Mn(III)PP, Ni(II)PP, Sn(IV)MP, Cr(IV)PP, and Co(III)PP were obtained from Frontier Scientific (Logan, UT). In all assays, ferriprotoporphyrin IX chloride was dissolved in dimethyl sulfoxide (designated in the text as hemin) or 0.05 N NaOH (designated as hematin) and kept in the dark before use. Human C1q isolated from plasma and human C-reactive proteins isolated from ascites were obtained by Calbiochem. Rituximab (Mabtera, Roche) was used as a source of human IgG1 with high purity. Endobulin (Baxter, Austria) was used as a source of pooled human IgG. Pneumococcal C-polysaccharide (PnC) was obtained from the Stenem Serum Institute (Copenhagen, Denmark). Human serum depleted of C1q and the kit for determination of sC5b-9 (MicroVue sC5b-9 Plus EIA kit) were obtained from Quidel (San Diego, CA). All buffers were prepared with ACS reagent grade chemicals.

Assessment of Classical Complement Pathway Activation in Presence of Heme—The level of complement activation in presence of C1q, exposed to increased concentrations of hemin was evaluated by C3 deposition ELISA, after addition of C1q-depleted serum. Microtiter plates were coated with 10 μg/ml pneumococcal C-polysaccharide as a natural ligand for CRP or 5 μg/ml tetanus toxoid as an antigen for IgG-containing immune complex formation. After blocking with 1% BSA, the wells were washed with 10 mM Tris, pH 7.4, 140 mM NaCl, 5 mM CaCl2, 0.05% Tween 20 for the plate coated with PnC or PBS with 0.05% Tween 20 for the plate coated with tetanus toxoid. CRP was applied at 1 μg/ml in 1% BSA-containing washing buffer for 1 h at 37 °C. Pooled human IgG at 0.5 mg/ml was applied on the tetanus toxoid-coated plate to form immune complexes. Anti-tetanus toxoid antibodies are present in the immunoglobulin preparation due to common vaccination against tetanus. After washing of all plates with 10 mM Hepes, pH 7.4, 100 mM NaCl, 5 mM CaCl2, 1 mM MgCl2, 0.05% Tween 20, intact or hemin-treated C1q was applied. For treatment of C1q with hemin, purified protein at 0.1 μM was incubated with increasing concentrations (0–15 μM) of hemin for 20 min at 4 °C in the dark. After incubation, the samples were diluted with washing buffer to a final C1q concentration of 1 nM (C1q molecular mass, 460 kDa) and applied at 50 μl/well to the microtiter plates. After incubation for 1 h at 37 °C, the plates were washed and either developed with anti-C1q-HRP (Abcam), or 50 μl of C1q-depleted serum (Quidel) diluted 1/400 with the washing buffer was added. The plates were then incubated for 1 h at 37 °C. After washing, the plates were incubated with biotinilated rabbit polyclonal anti-C3 antibody (diluted 1/500) or chicken anti-human C3 (Biodesign, diluted 1/10,000) for 1 h at 37 °C, followed by incubation with streptavidin-HRP for 30 min or goat anti-chicken HRP at 37 °C. Alternatively, anti-membrane attack complex (MAC) neoantigen-specific antibody-HRP (Quidel) was added to reveal the MAC formation. The reaction was developed by using tetramethylbenzidine (Sigma-Aldrich) substrate system and stopped by adding 1 M H2SO4. The level of C3 deposition in the presence of C1q, without hemin was considered as 100%, and the percentage of inhibition was scored for each hemin concentration. The optimal CRP, IgG, C1q concentration, and C1q-depleted serum dilution were determined prior running the experiment. To assure that the observed C3 deposition is due to activation of the classical pathway without being amplified by the alternative pathway, a serum dilution factor of 1/400 was used. To determine the level of soluble C5b-9 released in the fluid phase during the incubation with C1q-depleted serum, the supernatants from the wells were transferred to sC5b-9-specific ELISA (Quidel) and developed according to the manufacturer’s instructions. Wells, where coating with IgG1 or CRP was omitted, served as a control for the baseline level of sC5b-9 present in the C1q-depleted serum.

Thermodynamics of Interaction of Native and Heme-exposed C1q to IgG1 and mCRP—The kinetic constants of the binding of C1q to IgG1 and CRP were determined as a function of temperature by using BIAcore 2000 system. Human IgG1 and CRP were immobilized on research grade CM5 sensor chip, as described in the supplemental data. Kinetic experiments were performed using PBS as sample dilution and running buffer. C1q (0.1 μM) was treated with 2.5 μM hemin or with vehicle for 5 min at 4 °C. Native and hemin-exposed C1q were injected sequentially over the sensor surface at concentrations of 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.0312, and 0.0156 nM. The samples were always injected with flow rate of 10 μl/min. The association and dissociation were monitored for 5 min. Regeneration of the chip surface was performed by a 30-s exposure to 1.25 mM guanidine-HCl. All kinetic measurements were performed at temperatures of 10, 15, 20, 25, 30, and 35 °C. BIAevaluation 4.1 software (Biacore) was used for the evaluation of the rate constants by global analysis of the experimental data using a model of Langmuir binding with correction of the drifting baseline.

Evolution of the thermodynamic parameters (ΔH, TΔS, and ΔG) of the binding of C1q to its targets was performed as described previously (28). Further details are given in supplemental data.

Absorbance Spectroscopy—Absorbance spectra of hemo were recorded by using UNICAM Helios b, UV-visible spectrophotometer. Human C1q was diluted to 0.2 or 0.4 μM in PBS, pH 7.4. Aliquots of hemo, resulting in final concentrations in the range of 0.01 to 20.5 μM were added to an optical cell containing C1q and to a reference optical cell containing PBS only. The absorbance spectra in the wavelength range of 350–700 nm were read after addition of each aliquot of hemo and incu-
bation for 2 min in the dark at 20 °C. The spectra were recorded at a rate of 1500 nm/minute. The data of difference of the absorbance of protein bound hemin from free hemin at absorbance maxima (λ = 395 nm) in the Soret region were used to build titration binding curves. The data were fitted by using GraphPad Prism software (version 5.0) to the single binding site hyperbolic equation: $y = \Delta A_{\text{max}} \times (K_d + x)$, where $x$ is the concentration of hemin, $\Delta A_{\text{max}}$ is the maximal change in the absorbance intensity, and $K_d$ is the apparent equilibrium dissociation constant. The effect of the imidazole on the spectral characteristics of hemin was studied by addition of imidazole at final concentration of 2 mM to optical cell containing 12.8 μM hemin only or 12.8 μM hemin in the presence of 0.2 μM C1q. The absorbance spectra were measured as described above.

Fluorescence Spectroscopy

**Quenching of Intrinsic C1q Fluorescence by Heme**—Fluorescence spectra were recorded with a Hitachi F-2500 fluorescence spectrophotometer (Hitachi Instruments, Inc., Wokingham, UK). C1q was diluted to 0.5 μM in PBS, pH 7.4. The emission spectra of tyrosine and tryptophans after excitation at 280 nm and at 295 nm, respectively, were recorded in a 1-cm quartz cell. The excitation and emission slits were 10 nm. The spectra were recorded in a wavelength range of 300–500 nm with a scan speed of 1500 nm/min. Increasing aliquots of heme stock solutions were added directly into the optical cell containing C1q solution. After intensive homogenization and a 2-min incubation in the dark, the emission spectra were recorded. All measurements were performed at 20 °C.

**Fluorescence of Zn(II) Protoporphyrin IX Bound to C1q**—Spectrofluorimetric analysis of the binding of Zn(II)PP to human C1q were performed in PBS, pH 7.4, by using a Hitachi F-2500 fluorescence spectrometer. Aliquots of Zn(II)PP dissolved in dimethyl sulfoxide were added to C1q solution (0.1 μM) or to buffer only to increasing concentrations of 0.010–5.12 μM. Samples were then homogenized and allowed to stand in the dark for 2 min at 20 °C. Emission spectra of Zn(II)PP in the wavelength range 550–700 nm were recorded after excitation of at 410 nm. The excitation and emission slits were set to 10 nm. The rate of wavelength scan was 1500 nm/min. All measurements were performed in a 1-cm quartz cell at 20 °C.

**Measurement of Binding of Heme to C1q by Surface Plasmon Resonance**

The interaction of heme with C1q was studied by surface plasmon resonance (BIAcore). In brief, C1q were diluted in 5 mM maleic acid, pH 5, to a final concentration of 5 μg/ml and injected on an EDC/NHS-activated flow cell. The experiments were performed using PBS, pH 7.4. Hemin solutions were prepared by diluting the stock in PBS just before injection. Hemin was injected manually on immobilized C1q at concentrations of 0.05, 0.1, 0.25, 0.5, 0.75, and 1 μM with a flow rate of 20 μl/min. The association and dissociation phases of the interaction of hemin with C1q were monitored for 7 and 10 min, respectively. Regeneration of the chip surface was achieved by brief exposure (30 s) to a solution containing 0.05 M NaOH and 0.5 M NaCl. The binding to the surface of the control flow cell was always subtracted from the binding to the C1q-coated flow cells. BIAevaluation software (version 4.1; Biacore) was used for the evaluation of the kinetic rate constants.

**Size-exclusion Chromatography**

The molecular composition of native and heme exposed C1q was analyzed by using an FPLC Akta Purifier 10 (GE Healthcare Europe) system with a Superose-12 column equilibrated with PBS, pH 7.4. C1q (2.17 μM) was incubated for 10 min on ice with 43.4 μM hemin, giving 20-fold molar excess. One hundred μl of native or heme-exposed C1q were diluted to final volume of 1 ml with PBS. The samples were loaded to 30 ml Superose 12 column. Detection was set at a dual wavelength, at 280 nm for presence of protein and 405 nm for presence of hemin.

**Molecular Docking of Heme to gC1q**

The atomic coordinates of gC1q (Protein Data Bank code 1PK6) containing a Ca2+ ion (29) were used for the molecular docking. An apoform was created by omitting the Ca2+ ion, as described previously (30). AutoDock (version 3.0.5) (31) was used to accommodate the heme molecule to gC1q. Options for rigid protein and flexible heme were applied. Independently, Hex 6.1 and HexServer (32, 33) were utilized considering or not the electrostatic interactions. Because both docking partners are rigid-body structures, heme molecules (both in normal and in upset planes) from Protein Data Bank codes of different hemoproteins were selected. The criteria for final gC1q–heme complex selection were based on the total energy of binding. The final representative complexes were chosen statistically.

**Electrostatic Analysis of gC1q–Heme Complex**

Electric moments determinations were performed using the PHEMTO sever (Institute of Organic Chemistry, Biophysical Chemistry Lab at Bulgarian Academy of Sciences) as described previously (34, 35). PHEMTO (PH-dependent Electric Moments of proteins TOols) uses three different approaches to calculate three-dimensional electrostatic potentials grid(s) of proteins and their complexes. As a main function, it predicts explicitly the scalar and the orientation of electric moments, μ, (in particular the dipole moment ($\mu_d$) when $Z = 0$, i.e. in the isoelectric point, pi) based on space integration of the electrostatic potential. A variety of molecular viewers (RasMol, Jmol, and Chimera) were used for results visualization and analysis.

**RESULTS**

**Heme Is an Inhibitor of Classical Complement Pathway**—Immune complexes and CRP are important targets for C1q binding and subsequent classical pathway activation, leading to C3 deposition. Here, we assessed whether native and heme-exposed C1q have different abilities to activate the classical complement pathway on IgG and CRP-coated surfaces. C1q was allowed to interact with ligand-bound CRP (PnC-CRP as described in Ref. 36) or IgG-containing immune complexes. Fifteen μM hemin inhibited up to 90% of the binding of C1q to the immune complexes and ~30% of the binding of C1q to PnC-CRP complexes.
Heme Inhibits C1q

To this end, different metalloporphyrins were used that differ in their coordination chemistries. Co(III)PP, Mg(II)PP, and Zn(II)PP were found to inhibit strongly the interactions of C1q with its targets. In a contrast exposure of C1q to Sn(IV)MP, Mn(III)PP and Cr(III)PP had only negligible inhibitory effect (Fig. 2A), and Ni(II)PP had an intermediate inhibitory activity on the IgG and CRP binding.

To rule out the possibility that heme causes changes in the surface-bound IgG or CRP that further affect C1q binding, we pretreated surface-bound IgG and CRP with the highest concentration of heme introduced with C1q in our analyses. The injection of native C1q afterward showed binding profiles identical with the binding of native C1q on the untreated chip surface (data not shown).

**Kinetic and Thermodynamic Characterization of Heme-mediated Inhibition of C1q Interactions**—To understand the mechanism of heme-mediated inhibition of C1q interactions, we performed kinetic and thermodynamic analyses. The association and dissociation rate constants of binding of native and heme-exposed C1q (0.1 μM C1q exposed to 2.5 μM of hemin) to IgG1, mCRP, and pCRP were evaluated as a function of the temperature. The association rate constants of the interaction of native C1q with IgG1 and both forms of CRP showed identical temperature dependence. Thus, for the binding of C1q to proteins, the increase in the temperature resulted in a concomitant increase in the association rate (i.e. negative slopes in left panels of Fig. 3). Exposure of C1q to hemin resulted in qualitative and quantitative differences in the temperature dependence of $k_a$ of the interaction with IgG1 (Fig. 3); the association rate was reduced in the whole temperature range, and the temperature dependence was opposite to that of native C1q (Fig. 3A, left panel). Thus, an increase in the temperature resulted in the decrease of the association constant of hemin-exposed C1q to IgG1. The change in the temperature had similar effect on $k_a$ for hemin-exposed C1q and native C1q when the binding to mCRP was studied (Fig. 3B, left panel). However, the slope of the Arrhenius plot was greater in the case of hemin-treated C1q, implying a higher temperature sensitivity of the association rate. In contrast, the hemin exposure decreased the temperature sensitivity of association rate constant for the binding to pCRP.

The effect of the temperature on the dissociation rate constant was similar for all studied interactions. The increase of the temperature resulted always in an increase in the rates of dissociation (Fig. 3, right panels).

Differences in the temperature sensitivity of the rate constants of native and hemin-exposed C1q reflect differences in molecular mechanism of targets recognition. To characterize the biophysical mechanism of C1q interactions, we determined the changes in the thermodynamic parameters. The changes in enthalpy ($\Delta H$), entropy ($\Delta S$), and free energy ($\Delta G$) were evaluated for the association and dissociation phases, as well as for equilibrium of the binding of native and hemin-exposed C1q to IgG1 and both forms of CRP (Fig. 4). The exposure of C1q to hemin resulted in qualitative and quantitative changes in the thermodynamic parameters of the association in case of the three studied targets (Fig. 4). In contrast, the energetic changes during the dissociation phase of C1q interactions were less...
affected by the presence of hemin (Fig. 4). The thermodynamic changes at equilibrium indicated that C1q binding to mCRP and pCRP occur by identical mechanism that differed qualitatively from those typical for IgG1 (Fig. 4).

Heme Binds to C1q—We hypothesized that the inhibition of C1q recognition of its targets may result from a direct interaction of heme with C1q. The specific electronic characteristics of heme allow investigating its binding to proteins by spectroscopic approaches. A UV-visible absorbance spectrum of oxidized heme showed an increase in the molar extinction coefficient at the Soret band (400 nm) in the presence of C1q (Fig. 5A). The titration of C1q with increasing concentrations of hemin resulted in saturable (at 12-fold heme excess) increase in the differential spectrum at the Soret band. These data indicate that hemin binds to C1q molecule and that each C1q molecule

binds 12 hemin molecules (i.e. two hemin molecules per gC1q).

Furthermore, we studied the effect of imidazole on the heme electronic properties (Fig. 5B). Incubation of hemin with imidazole resulted in a red-shift in the Soret band and the appearance of two absorbance peaks in the 425 nm region of the spectrum. These changes are consistent with a transition of the heme iron to a bis-imidazole hexacoordinated low spin state. The addition of imidazole to C1q preincubated with hemin resulted in less pronounced changes in the absorbance spectrum of hemin, indicating the engagement of hemin in an interaction with the protein that may reduce the ability of imidazole to coordinate the heme iron.

To further confirm binding of hemin to C1q and to characterize the kinetics of the interaction, we applied a surface plasmon resonance-based technique. Injection of hemin over...
immobilized C1q resulted in a concentration-dependent increase in hemin binding to C1q (Fig. 5C). Evaluation of the kinetic parameters of the interaction revealed that hemin binds to C1q with an affinity in the 1–2 μM range. The interaction was characterized by a slow association, $k_a$ of $3.2 \times 10^3$ M$^{-1}$ s$^{-1}$ and a relatively fast dissociation, $k_d$ of $3.44 \times 10^3$ s$^{-1}$. By using size-exclusion chromatography (Fig. 5D), we analyzed the molecular integrity of C1q after exposure to hemin at concentrations that are able to significantly inhibit C1q binding to its targets (Figs. 1 and 2). The elution profile of hemin-C1q did not differ from that of C1q alone, indicating that heme treatment is not inducing aggregation of C1q. Size-exclusion chromatography analyses also confirmed that heme forms stable complexes with C1q. Thus, when C1q was treated with hemin, the elution of the protein, detected by absorbance at 280 nm, coincided with elution of hemin, detected by its specific absorbance at 405 nm (Fig. 5D).

Another evidence for hemin binding to C1q was provided by using fluorescence spectroscopy. Titration of C1q with increasing concentrations of hemin resulted in quenching of the intrinsic fluorescence of aromatic residues (mainly of Tyr and Trp excited at 280 nm) and more specifically of Trp (excited at 295 nm) in C1q (Fig. 5E). These results suggested that hemin binds in close vicinity to aromatic residues.

Finally, we studied the ability of the fluorescence compound Zn(II)PP, which differs from heme only by the nature of its central metal, to bind to C1q. Spectroscopy analyses revealed that incubation of C1q in the presence of Zn(II)PP resulted in an increase in the fluorescence intensity of the porphyrin (Fig. 5F), which was saturated at the highest concentration used (data not shown). These data indicate that C1q is able to bind Zn(II)PP and highlight the importance of the porphyrin ring in the interaction.

Heme-induced Alteration of Electrostatic Properties of gC1q—The attempt to dock heme to gC1q by using AutoDock resulted in a large number of possible structures with close values of the binding energy. The preferred binding site appeared to be located in the lower part of the heterotrimer, close to the collagen-like part. The complexes obtained using Hex and HexServer with and without electrostatic contributions gave less scattering of the possible binding sites and allowed us to select two models (Fig. 6), representing the most probable site (with lowest value of energy) with (Fig. 6A) and without (Fig. 6B) taking into account the electrostatic contributions. In both cases, heme is located at the lower part of gC1q, bound to the A-chain (Fig. 6A, A-model) or to the C-chain (Fig. 6B, C-model).

The residues that make a direct contact with heme in the A-model are as follows: ValA$^{114}$, IleA$^{115}$, AsnA$^{117}$, GluA$^{119}$, GluA$^{120}$, AsnA$^{124}$, ArgB$^{129}$, LysB$^{188}$, and GluB$^{190}$ (supplemental Fig. 1A). The closest aromatic residue is TyrA$^{122}$, which is at
The contact residues for heme in the C-model are as follows: ValB_{118}, IleB_{119}, ThrB_{120}, AsnB_{121}, MetB_{122}, AspC_{156}, ArgC_{182}, LeuC_{183}, GlnC_{184}, GluC_{187}, and AspC_{217}, with TrpC_{190} being at less than 10 Å away from the heme (supplemental Fig. 1). The two binding sites may be occupied simultaneously.

To get an insight to the mode of heme-induced inhibition, the value and the direction of the electric moment vectors were calculated for the free gC1q and the two selected heme-containing complexes in a large pH range. At a pH interval of 5–11, all vectors are directed toward heme moieties, mainly through the A-chain for the A-model and fixed through the iron-heme atom on the C-model. The position of the vectors does not depend on the presence or absence of the Ca^{2+} ion. These directions strongly differ from the ones in the native gC1q in presence of Ca^{2+}/H_{11001} (directed toward the apex of gC1q) or in a Ca^{2+}-free state (toward the lateral surface of the B-chain). In case of simultaneous occupancy of the two binding sites, the electric moment vector remains directed toward the apex of the heterotrimer as in the native (Ca^{2+}/H_{11001}-bound) form, but cannot be redirected when the Ca^{2+} ion is removed.

**DISCUSSION**

In this study, we demonstrated that heme is able to inhibit IgG- and CRP-mediated complement activation by direct binding to C1q. The inhibitory effect of heme resulted from alterations in the molecular mechanism that drives the interaction of C1q with its targets. Spectroscopic and biosensor analyses revealed that heme binds to C1q with micromolar equilibrium affinity. Heme binding to C1q was saturable with two binding sites for each of the six gC1q domains. The spectral data obtained by absorbance and fluorescence spectroscopy suggest that binding of heme to C1q is not accompanied by changes in its molecular environment. The absence of shifts in the absorbance maxima implies that heme most probably bind to the surface of the protein. Heme is a hydrophobic compound and has a tendency to interact with hydrophobic regions of proteins. The marked quenching of the intrinsic Trp and Tyr fluorescence of C1q by hemin indicates that heme forms contacts at regions that are rich in aromatic residues. The collagen-like region of C1q is composed primarily of glycine-hydroxyproline-hydroxylysine repeats. The majority of the aromatic residues are found in the globular domains, the surface of which consists of charged and hydrophobic patches (5, 29). In accordance with the experimental results, the data obtained by molecular docking of heme to the structure of gC1q suggested that heme binds to the surface of the protein, in close proximity to TyrA_{122} (for the binding site in the A-chain) and to TrpC_{190} (for the binding site in the C-chain).
The thermodynamic analyses of interactions of native and heme-exposed C1q indicate that reduced binding of heme-C1q to its targets is mainly due to unfavorable changes in association thermodynamics. The changes in the thermodynamic parameters that characterize intermolecular recognition reflect the formation of noncovalent contacts (changes in enthalpy) and the presence of structural alternations in the interacting proteins (changes in entropy) (39–41). Negative values of the changes in the entropy during association are usually associated with “induced fit” binding of macromolecules, where the conformational heterogeneity (high entropy) of free binding partners is reduced (decrease in entropy) upon complex formation (40–42). Interestingly, the physicochemical mechanisms underlying the inhibitory effect of heme were not identical when the interactions of C1q with IgG1, and both forms of CRP were studied. The marked increase in the negative value of $\Delta T$ observed for the association of heme-bound C1q to IgG1 and to pCRP suggests that heme increases the structural flexibility of C1q; the energetic penalty of the structural adjustments of heme-bound C1q to IgG increases the activation energy of association and thus negatively influences the overall binding affinity. In contrast, the binding of heme-C1q to mCRP was characterized by a favorable contribution from $\Delta T$ (positive sign), implying the absence of structural changes during association. The latter interaction can be categorized as obeying to the “lock-and-key” recognition model, an interaction of preformed rigid binding sites. The reduction of the binding affinity of C1q for mCRP derives mainly from a highly unfavorable change in the association enthalpy. Thus, the binding of heme most probably prevents vital interactions of C1q with the binding partner.
noncovalent interactions between C1q and mCRP, resulting in a reduction of the binding affinity.

The thermodynamic analyses further provide important evidence about the mechanism of target recognition by the native C1q. These data indicate that native C1q associates to IgG monomeric and pentameric CRP by similar physicochemical mechanisms. However, quantitative differences in the association and the dissociation phase for the targets results in qualitative alteration of the equilibrium thermodynamics. Thus, in the case of IgG1, the interaction is driven by favorable changes in equilibrium enthalpy. In contrast, the binding to mCRP and pCRP is driven by favorable changes in equilibrium entropy. These data are supported by previous observations indicating that the binding sites for IgG and CRP may overlap but are not identical (30, 43, 44). The observed differences in the binding mechanism of native C1q also reflect the different nature of the target proteins.

Heme is not the only porphyrin capable of inhibiting the binding of C1q to IgG and CRP. We observed that Co(III)PP, Mg(II)PP, and Zn(II)PP also have potent inhibitory activity on the interactions of C1q. In contrast, porphyrins containing Cr(III), Mn(III), or Sn(IV) ions, or devoid of metal ions, such as hematoporphyrin IX, possess much lower potential to inhibit C1q. This result suggests that coordination of the central metal in the porphyrins by C1q plays an essential role for inhibitory activity. Indeed, the differences in the coordination geometries of different metals would result in different preferences and energies of coordination by particular amino acid residues in the protein.

Previous studies have demonstrated that other heterocyclic compounds structurally similar to heme are also able to inhibit C1q functions. Thus, unconjugated bilirubin, which is a product of heme catabolism, found at high concentrations in the case of liver diseases or of hemolytic anemia, binds to C1q and inhibits the classical complement pathway (45, 46). Moreover, synthetic heterocyclic compounds such as bisphenol disulfates, sulfated steroids, and triterpenoids also inhibit the classical complement pathway at the level of C1q (47, 48). Two of these compounds, betulin disulfate and 9,9-bis(4-hydroxyphenyl) fluorene disulfate, were studied in detail (43). They bind to gC1q and inhibit its interaction with IgG1 and CRP by modulating the electrostatic properties of the protein, reducing the scalar values, and altering the orientation of the electric moment vectors of gC1q. These dipole/electric moment effectors impair the electrostatic properties of C1q and consequently inhibit the complement activation. Here, we provide evidence that similar electric moments inhibition occurs with natural heterocyclic compounds such as heme. The iron ion appears to be important for this activity, as hematoporphyrin, which has the similar macrocyclic backbone but lacks the metal ion, inhibits C1q binding to a much smaller extent. Interestingly, heme, like bisphenol disulfates, sulfated steroids, triterpenoids, and bilirubin, share common structural features: two negative charges, separated by 8–12 Å by bulky hydrophobic groups in the central part of the molecules. These characteristics were demonstrated to be of importance for inhibition of the classical complemet pathway (47, 48) and may explain the inhibitory effect of heme. The binding sites for heme on C1q, predicted by molecular docking, are different from the ones predicted in the case of betulin disulfate and 9,9-bis(4-hydroxyphenyl) fluorene disulfate, but the effect on the electric moments orientation is similar. Yet, the binding of heme also results in a reorientation of the electric moment vectors of gC1q. We therefore hypothesize that heme is an endogenous electrostatic effector, which
Heme Inhibits C1q

alters the binding properties from C1q by modulation of its physicochemical characteristics.

A complement is a double-edged sword, capable of destroying invading pathogens but also of damaging self-tissues, as seen in many pathological conditions. Inappropriate complement activation has been shown to induce tissue injury in the context of severe inflammation, ischemia/reperfusion, transplantation, stroke, myocardial infarction, hemolytic anemia, immune complex diseases, malaria, and etc. (13–15, 49). Several natural inhibitors of the early steps of the classical pathway activation, like C1 inhibitor (50, 51) and C1q inhibitor (chondroitin-4-sulfate proteoglycan) (52), can counteract the deleterious effects induced by undesired complement triggering. However, in many situations, these systems are insufficient to prevent attack by the complement, and there is an urgent need for developing synthetic inhibitors of the early stages of classical pathway activation (12, 53, 54). A good understanding of the interaction between C1q and its target molecules is an indispensable step toward designing proficient inhibitors of the classical complement pathway. Based on our results, it is tempting to speculate that heme is an endogenous negative-feedback regulator of the activation of the classical complement pathway. Indeed, in cases where high levels of free heme are present, like malaria and ischemia/reperfusion, the classical complement pathway plays only a minor role (if any) despite of the presence of damaged cells (ligands for C1q) and activation of other pathways (49). The heme that is released during cellular damage may modulate the classical pathway triggered by immune complexes and CRP. This anti-inflammatory activity of free heme may be a natural last chance for rescue in such severe, life-threatening conditions. Novel, optimized molecules based on the heme scaffold could be candidates for future therapeutic agents.

REFERENCES

1. Walport, M. J. (2001) Nature 413, 117–128
2. Agrawal, A., Singh, P. P., Bottazzi, B., Garlanda, C., and Mantovani, A. (2009) Adv. Exp. Med. Biol. 653, 117–128
3. Thompson, D., Pepys, M. B., and Wood, S. P. (1999) Adv. Exp. Med. Biol. 459, 187–199
4. Eisenharter, S. U., Habersberger, J., Murphy, A., Chen, Y. C., Woollard, K. J., Bassler, N., Qian, H., von Zur Muhlen, C., Hagemeyer, C. E., Ahrens, I., Chin-Dusting, J., Bobik, A., and Peter, K. (2009) Circ. Res. 105, 125–137
5. Kallman, K. J., and Nolte, P. (2009) Adv. Exp. Med. Biol. 653, 117–128
6. Agrawal, A., Singh, P. P., Bottazzi, B., Garlanda, C., and Mantovani, A. (2009) Adv. Exp. Med. Biol. 653, 117–128
7. Thompson, D., Pepys, M. B., and Wood, S. P. (1999) Structure 7, 169–177
8. Volanakis, J. E. (2001) Mol. Immunol. 38, 189–197
9. Eisenharter, S. U., Habersberger, J., Murphy, A., Chen, Y. C., Woollard, K. J., Bassler, N., Qian, H., von Zur Muhlen, C., Hagemeyer, C. E., Ahrens, I., Chin-Dusting, J., Bobik, A., and Peter, K. (2009) Circ. Res. 105, 125–137
10. Ji, S. R., Wu, Y., Zhu, L., Potempa, L. A., Sheng, F. L., Lu, W., and Zhao, J. (2007) J. Biol. Chem. 282, 284–294
11. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
12. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
13. Griselli, M., Herbert, J., Hutchinson, W. L., Taylor, K. M., Sohail, M., Krausz, T., and Pepys, M. B. (1999) J. Exp. Med. 190, 1733–1740
14. del Zoppo, G. G. (1999) Nat. Med. 5, 995–996
15. Kumar, S., and Bandypadhyay, U. (2005) Toxicol. Lett. 157, 175–188
16. Wagener, F. A., Volk, H. D., Willis, D., Abraham, N. G., Soares, M. P., Adema, G. J., and Fidgór, C. G. (2003) Pharmacol. Rev. 55, 551–571
17. Muller-Eberhard, U., Javid, J., Lien, H. H., Hanstein, A., and Hanna, M. (1968) Blood 32, 811–815
18. Sears, D. A. (1970) J. Clin. Invest. 49, 5–14
19. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
20. Griselli, M., Herbert, J., Hutchinson, W. L., Taylor, K. M., Sohail, M., Krausz, T., and Pepys, M. B. (1999) J. Exp. Med. 190, 1733–1740
21. del Zoppo, G. G. (1999) Nat. Med. 5, 995–996
22. Kumar, S., and Bandypadhyay, U. (2005) Toxicol. Lett. 157, 175–188
23. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
24. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
25. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
26. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
27. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
28. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
29. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
30. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
31. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
32. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
33. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
34. Weiser, M. R., Williams, J. P., Moore, F. D., Jr., Kobzik, L., Ma, M., Hechtman, H. B., and Carroll, M. C. (1996) J. Exp. Med. 183, 2343–2348
35. Roos, A., Ramwadhdoebé, T. H., Nauta, A. J., Hack, C. E., and Daha, M. R. (2002) Immunobiology 205, 595–609
